Canada
· Delayed Price · Currency is CAD Profound Medical Statistics
Total Valuation
Profound Medical has a market cap or net worth of CAD 263.88 million. The enterprise value is 235.65 million.
| Market Cap | 263.88M |
| Enterprise Value | 235.65M |
Important Dates
The last earnings date was Friday, November 1, 2024.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Profound Medical has 24.66 million shares outstanding. The number of shares has increased by 12.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 24.66M |
| Shares Change (YoY) | +12.36% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 9.39% |
| Owned by Institutions (%) | 49.16% |
| Float | 22.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.86 |
| PB Ratio | 6.29 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.56 |
| EV / Sales | 19.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of 0.20.
| Current Ratio | 6.12 |
| Quick Ratio | 5.12 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -48.87 |
Financial Efficiency
Return on equity (ROE) is -90.17% and return on invested capital (ROIC) is -49.25%.
| Return on Equity (ROE) | -90.17% |
| Return on Assets (ROA) | -44.62% |
| Return on Capital (ROIC) | -49.25% |
| Revenue Per Employee | 92,648 |
| Profits Per Employee | -323,723 |
| Employee Count | 131 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.43% in the last 52 weeks. The beta is 0.81, so Profound Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -27.43% |
| 50-Day Moving Average | 10.67 |
| 200-Day Moving Average | 11.46 |
| Relative Strength Index (RSI) | 43.83 |
| Average Volume (20 Days) | 8,025 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Profound Medical had revenue of CAD 12.14 million and -42.41 million in losses. Loss per share was -1.79.
| Revenue | 12.14M |
| Gross Profit | 7.53M |
| Operating Income | -44.70M |
| Pretax Income | -42.40M |
| Net Income | -42.41M |
| EBITDA | -43.85M |
| EBIT | -44.70M |
| Loss Per Share | -1.79 |
Balance Sheet
The company has 36.64 million in cash and 8.41 million in debt, giving a net cash position of 28.23 million or 1.14 per share.
| Cash & Cash Equivalents | 36.64M |
| Total Debt | 8.41M |
| Net Cash | 28.23M |
| Net Cash Per Share | 1.14 |
| Equity (Book Value) | 41.97M |
| Book Value Per Share | 1.70 |
| Working Capital | 46.21M |
Cash Flow
| Operating Cash Flow | -33.54M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 62.02% |
| Operating Margin | -368.27% |
| Pretax Margin | -349.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Profound Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.36% |
| Shareholder Yield | -12.36% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 16, 2019. It was a reverse split with a ratio of 0.1.
| Last Split Date | Oct 16, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Profound Medical has an Altman Z-Score of 1.68. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.68 |
| Piotroski F-Score | n/a |